{"id":"W4379468067","doi":"10.1038/s41591-023-02399-0","title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Duke Cancer Institute; Chugai Pharmaceutical; Genentech; Menarini Group; PharmaMar; Astellas Pharma; Eisai; Springworks Therapeutics; Seagen; Mereo BioPharma; MacroGenics; Silverback Therapeutics; Actuate Therapeutics; Loxo Oncology; Astex Pharmaceuticals; Invitae; AstraZeneca; Novocure; Jazz Pharmaceuticals; Merck KGaA; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; Spectrum Pharmaceuticals; Mersana Therapeutics; Karyopharm Therapeutics; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; Daiichi Sankyo Europe; National Cancer Institute; Servier; Foghorn Therapeutics; Samsung; Bristol-Myers Squibb; Amgen; Memorial Sloan-Kettering Cancer Center; Massachusetts General Hospital; GlaxoSmithKline","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Cancer; Ataxia-telangiectasia; Cancer research; Oncology; Clinical trial; Internal medicine; DNA damage; Pharmacology; Biology; DNA; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001713724,0.0002258383,0.0003244339,0.0002572082,0.0000552111,0.000007215688,0.0002949796,0.0004105678,0.00001817845],"category_scores_gemma":[0.004218185,0.0001842464,0.00007351832,0.0006309417,0.00009839311,0.000004079339,0.000125907,0.0004648498,0.0000284105],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004207848,"about_ca_system_score_gemma":0.0001327312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001429801,"about_ca_topic_score_gemma":0.00007156201,"domain_scores_codex":[0.9978749,0.0002287234,0.0004811508,0.0005967966,0.0003910012,0.000427385],"domain_scores_gemma":[0.9988756,0.0001049137,0.0001313294,0.0006654305,0.00008737813,0.0001353179],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.09118624,0.0001266042,0.000006601666,0.00001178459,0.00001248009,0.0002063743,0.0002034004,0.0000328524,0.8984455,0.0000278798,0.008698459,0.001041866],"study_design_scores_gemma":[0.1080167,0.005720109,0.0008389965,0.0002181434,0.00002018031,0.00002042642,0.000552103,0.0003269797,0.8314507,0.000103502,0.05242671,0.0003054266],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940404,0.000517634,0.00002049834,0.002949074,0.0009821106,0.0006083766,0.00004890393,0.00009605702,0.0007369621],"genre_scores_gemma":[0.9950467,0.00005617978,0.0001227868,0.000803007,0.0005654097,0.00005931489,0.0004669737,0.00003945159,0.002840158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06699476,"threshold_uncertainty_score":0.7513349,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01098829602532976,"score_gpt":0.3373821352244508,"score_spread":0.3263938391991211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}